PPP2R5D

Across TCGA pan-cancer cohorts, PPP2R5D Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PPP2R5D data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PPP2R5D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP2R5D expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, LIHC, and COAD are the cancer types where PPP2R5D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.126	0.579	<.001	40	view →
LIHC	OS	Median	II,III,IV	0.093	0.696	<.001	24	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
UCEC	DFS	Median	All	0.924	0.619	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PPP2R5D–BRCA (OS)

Open the BRCA breakdown →